ECG
VIR icon

EPIQ Capital Group’s Vir Biotechnology VIR Stock Holding History

EPIQ Capital Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,043
Closed -$411K – 46
2020
Q2 		$411K Buy
+10,043
New +$337K 0.07% 30

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EPIQ Capital Group's VIR Position: Q3 2020 in Review

EPIQ Capital Group sold out of Vir Biotechnology (VIR) in Q3 2020, closing a stake of 10,043 shares — an estimated $411K sold.

EPIQ Capital Group first reported a position in VIR in Q2 2020 and held it in 1 quarter. The position peaked at $411K in Q2 2020. 119 funds tracked by Wall St. Rank hold VIR as of Q3 2020.

  • EPIQ Capital Group reported no remaining Vir Biotechnology position as of Q3 2020 after selling out during the quarter.
  • EPIQ Capital Group sold 10,043 Vir Biotechnology shares in Q3 2020, an estimated $411K.
  • EPIQ Capital Group first reported a position in Vir Biotechnology in Q2 2020 and held it in 1 quarter.
  • EPIQ Capital Group's Vir Biotechnology position peaked at $411K in Q2 2020.
  • 119 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2020.

Based on EPIQ Capital Group's 13F filing for Q3 2020, filed 6 Nov 2020.